+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Dementia (Central Nervous System) - Drugs In Development, 2021

  • ID: 5359591
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 682 pages
  • Global Markets Direct

FEATURED COMPANIES

  • AbbVie Inc
  • AFFiRiS AG
  • AlphaCognition Inc
  • Aprinoia Therapeutics Inc
  • Inventage Lab Inc
  • Kogenix Therapeutics Inc
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dementia (Central Nervous System) - Drugs In Development, 2021, provides an overview of the Dementia (Central Nervous System) pipeline landscape.

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Dementia (Central Nervous System) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 13, 35, 31, 2, 79, 41 and 2 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 13, 5 and 1 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • AFFiRiS AG
  • AlphaCognition Inc
  • Aprinoia Therapeutics Inc
  • Inventage Lab Inc
  • Kogenix Therapeutics Inc
  • MORE
  • Introduction
  • Dementia - Overview
  • Dementia - Therapeutics Development
  • Dementia - Therapeutics Assessment
  • Dementia - Companies Involved in Therapeutics Development
  • Dementia - Drug Profiles
Dementia - Dormant Projects

Dementia - Discontinued Products
  • Dementia - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Dementia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Dementia - Pipeline by AbbVie Inc, 2021
  • Dementia - Pipeline by Acadia Pharmaceuticals Inc, 2021
  • Dementia - Pipeline by Actinogen Medical Ltd, 2021
  • Dementia - Pipeline by AcuraStem Inc, 2021
  • Dementia - Pipeline by Adamed Sp zoo, 2021
  • Dementia - Pipeline by ADEL Inc, 2021
  • Dementia - Pipeline by AFFiRiS AG, 2021
  • Dementia - Pipeline by AgeneBio Inc, 2021
  • Dementia - Pipeline by AIBIOS Co Ltd, 2021
  • Dementia - Pipeline by Alector Inc, 2021
  • Dementia - Pipeline by Alkermes Plc, 2021
  • Dementia - Pipeline by AlphaCognition Inc, 2021
  • Dementia - Pipeline by Alterity Therapeutics Ltd, 2021
  • Dementia - Pipeline by Amarantus Bioscience Holdings Inc, 2021
  • Dementia - Pipeline by Anavex Life Sciences Corp, 2021
  • Dementia - Pipeline by Annovis Bio Inc, 2021
  • Dementia - Pipeline by Aphios Corp, 2021
  • Dementia - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, 2021
  • Dementia - Pipeline by Yumanity Therapeutics Inc, 2021
  • Dementia - Dormant Projects, 2021
  • Dementia - Discontinued Products, 2021
List of Figures
  • Number of Products under Development for Dementia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021
Note: Product cover images may vary from those shown
  • AbbVie Inc
  • Acadia Pharmaceuticals Inc
  • Actinogen Medical Ltd
  • AcuraStem Inc
  • Adamed Sp zoo
  • ADEL Inc
  • AFFiRiS AG
  • AgeneBio Inc
  • AIBIOS Co Ltd
  • Alector Inc
  • Alkermes Plc
  • AlphaCognition Inc
  • Alterity Therapeutics Ltd
  • Amarantus Bioscience Holdings Inc
  • Anavex Life Sciences Corp
  • Annovis Bio Inc
  • Aphios Corp
  • Applied Genetic Technologies Corp
  • Aprinoia Therapeutics Inc
  • Aptinyx Inc
  • AriBio
  • Arkuda Therapeutics Inc
  • IntraBio Ltd
  • Inventage Lab Inc
  • IRLAB Therapeutics AB
  • Jazz Pharmaceuticals Plc
  • Johnson & Johnson
  • KeifeRx LLC
  • Kogenix Therapeutics Inc
  • Korea Pharma Co Ltd
  • Kwang Dong Pharmaceutical Co Ltd
  • Lachesis Biosciences Ltd
  • Locanabio Inc
  • Whan In Pharm Co Ltd
  • Yumanity Therapeutics
  • Yumanity Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll